Found 49 Solid Tumors trials
A listing of Solid Tumors medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.
Please refer to Protocol D9350C00001, Section 3 (Objectives and Endpoints) Please refer to Protocol D9350C00001, Section 3 (Objectives and Endpoints) Please refer to Protocol D9350C00001, Section 3 (Objectives and Endpoints)
Please refer to Protocol BNT142-01, section 1.1 Trial synopsis, Objectives and endpoints. Please refer to Protocol BNT142-01, section 1.1 Trial synopsis, Objectives and endpoints. Please refer to Protocol BNT142-01, section 1.1 Trial synopsis, Secondary objectives.
The purpose of this study includes the following: · To test the efficacy and safety of the Study Drug and to find out what effects, good and/or bad, it has on you and your cancer. · To understand how the body absorbs and processes the Study Drug by measuring the …
Please refer to Protocol Section 2 (Objectives and Endpoints) Please refer to Protocol Section 2 (Objectives and Endpoints) Please refer to Protocol Section 2 (Objectives and Endpoints)
To assess safety and tolerability, including dose-limiting toxicities (DLTs), maximum tolerated dose (MTD), or maximum administered dose (MAD; if no MTD is defined) of IMGN151 when administered intravenously To determine recommended Phase 2 dose (RP2D) for IMGN151 To characterize the pharmacokinetics (PK) and immunogenicity of IMGN151 -To assess ORR for …
This is a Phase 1, multiple-dose, ascending dose-escalation and expansion study of XmAb22841, both as a monotherapy and in combination with pembrolizumab. The study is designed in 2 parts, Part A and Part B. Part A is a 3 + 3 dose escalation designed to assess both XmAb22841 administered as …
ASTX295 is a synthetic small molecule that acts as an antagonist of Murine Double Minute 2 (MDM2; human homolog also known as HDM2). Study ASTX295-01 is a study with ASTX295 in subjects who are refractory or have relapsed after treatment with standard of care therapies, or for whom standard life-prolonging …
This is a Phase I dose-escalation and dose-expansion study that will evaluate the safety, pharmacokinetics (PK), and preliminary activity of GDC-6036 in patients with advanced or metastatic solid tumors with a KRAS G12C mutation.
The purpose of this study is to continue to collect long term information on the safety of pembrolizumab or pembrolizumab-based combinations that you received or are receiving as part of the protocol you are currently enrolled in, to see how well the drug/s work and how your body reacts to …
NP-G2-044 Monotherapy Primary Objectives The primary objectives for patients receiving NP-G2-044 monotherapy are the following: 1) to identify the recommended Phase 2 dose (RP2D) of continuously dosed NP-G2-044 monotherapy (Mono-RP2D) and characterize its safety; and 2) to assess preliminary signals of NP-G2-044 anti-tumor efficacy when administered as continuously dosed monotherapy.
